Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 15, 2025
Outcomes of Reinduction With Nadofaragene Firadenovec.
Journal: The Journal of urology
Published: August 25, 2025
Durability of response of UGN-101: Longitudinal follow up of multicenter study.
Journal: Urologic oncology
Published: September 02, 2024
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Journal: Nature medicine
Published: July 02, 2024
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Journal: Nature medicine
Published: June 18, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Journal: Nature medicine
Published: April 05, 2024
Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials.
Journal: Urologic oncology
Published: November 12, 2023
Corrigendum to "Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes" [Eur. Urol. Focus (2023)].
Journal: European urology focus
Published: August 28, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergency.
Journal: Urologic oncology
Published: July 25, 2023
First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors.
Journal: Urologic oncology
Published: May 04, 2023
Last Updated: 09/26/2026